Marshall Wace
EWTX icon

Marshall Wace’s Edgewise Therapeutics EWTX Stock Holding History

Marshall Wace’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Sell
6,100
-642,293
-99% -$22.1M ﹤0.01% 2771
2026
Q1 		$20.4M Sell
648,393
-33,528
-5% -$967K 0.02% 698
2025
Q4 		$16.9M Buy
+681,921
New +$13.7M 0.02% 685
2025
Q1 		– Sell
-29,893
Closed -$798K – 2753
2024
Q4 		$798K Sell
29,893
-547,672
-95% -$17.4M ﹤0.01% 1834
2024
Q3 		$15.4M Buy
577,565
+161,845
+39% +$3.22M 0.02% 597
2024
Q2 		$7.49M Buy
415,720
+361,103
+661% +$6.3M 0.01% 850
2024
Q1 		$996K Buy
+54,617
New +$868K ﹤0.01% 1652

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's EWTX Position: Q2 2026 in Review

Marshall Wace reduced its Edgewise Therapeutics (EWTX) stake by 99% in Q2 2026, selling an estimated $22.1M and leaving 6,100 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

Marshall Wace first reported a position in EWTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $20.4M in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Marshall Wace held 6,100 shares of Edgewise Therapeutics worth $248K as of Q2 2026.
  • Marshall Wace sold 642,293 Edgewise Therapeutics shares in Q2 2026, an estimated $22.1M.
  • Edgewise Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2771 holding.
  • Marshall Wace first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Marshall Wace's Edgewise Therapeutics position peaked at $20.4M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.